ABSTRACT
Despite significant advances over the past 40 years in areas of immunology, biochemistry, and genetics, the ways in which disease processes and their therapies are studied in patients have changed little. Traditionally, patient-based research has been oriented around the drug approval process which, in the case of the United States, is mediated largely through phase I, II, and III trials for FDA approval of new therapies.
